Open menu

Nanotechnology Spotlight

Behind the buzz and beyond the hype:
Our Nanowerk-exclusive feature articles

RSS Subscribe to our Nanotechnology Spotlight feed

Showing Spotlights 57 - 64 of 82 in category Social Issues, Ethics, History, Art (newest first):

 

Ethical aspects of nanotechnology in medicine

ethics_of_nanomedicineFor centuries, man has searched for miracle cures to end suffering caused by disease and injury. Many researchers believe nanotechnology applications in medicine may be mankind's first 'giant step' toward this goal. According to Freitas nanomedicine is "...(1) the comprehensive monitoring, control, construction, repair, defense, and improvement of all human biological systems, working from the molecular level, using engineered nanodevices and nanostructures; (2) the science and technology of diagnosing, treating, and preventing disease and traumatic injury, of relieving pain, and of preserving and improving human health, using molecular tools and molecular knowledge of the human body; (3) the employment of molecular machine systems to address medical problems, using molecular knowledge to maintain and improve human health at the molecular scale." Nanomedicine not only has the potential to change medical science dramatically but to open a new field of human enhancements that is poised to add a profound and complex set of ethical questions for health care professionals. For instance, there is a fine line between medical and non-medical uses of nanotechnology for diagnostic, therapeutic and preventive purposes (e.g. non-medical implants in soldiers). The question of whether nanotechnology should be used to make intentional changes in or to the body when the change is not medically necessary is just one hot topic in a long list of concerns. The good news is that these questions are being asked, but there is still much work to be done, but despite the enormous promise of nanomedicine, and the considerable funding going into the field, the research into the ethical, legal and social implications of nanomedicine is comparatively minute. As Peter Singer wrote in his 2003 tutorial Mind the gap: science and ethics in Nanotechnology: 'The science leaps ahead, the ethics lags behind.' As with nanotechnology in general, there is danger of derailing nanomedicine if the study of ethical, legal and social implications does not catch up with scientific developments.

Posted: Jan 8th, 2008

Secret military nanotechnology development

Given past revelations of previously top secret military technology programs there is a good chance that some 'black' projects somehwere tinker with advanced nanotechnology applications. But, you keepers of military secrets, relax. This Spotlight is not a piece of investigative journalism into the world of military black projects. It is the first in a series of eight scenarios that have just been published by the Center for Responsible Nanotechnology (CRN) - and we here at Nanowerk have posted the entire nanotechnology scenario project here. CRN's scenarios depict various versions of a near-future world into which transformative manufacturing concepts may emerge. Across eight separate storylines, an international team of policy, technology, and economic specialists organized by CRN imagined in detail a range of plausible, challenging events - from pandemics to climate crises to international conflicts - to see how they might affect the development of advanced nanotechnology over the next 15 years. Please keep in mind that this and the others seven scenarios are NOT predictions but fiction. CRN intends the scenarios to provide a springboard for discussion of molecular manufacturing policies and societal responses. While each scenario can be understood individually, the real value of the process comes from the comparison of multiple scenarios. A strategic response that appears robust in one scenario may be dangerous in another; an organization, community, or polity using these scenarios to consider how to handle the emergence of molecular manufacturing should strive for responses that are viable across multiple scenarios.

Posted: Dec 12th, 2007

Implementing successful voluntary nanotechnology environmental programs appears to be a challenge

Governments always struggle when faced with regulating highly complex subject matters such as nanotechnologies. Primarily concerned with managing the potential risks to the environment, human health and the safety of workers (EHS), regulators often feel overwhelmed by the complexity and novelty of new technologies, stymied by a lack of data, and confused by conflicting research findings and advice from various interest groups. In the meantime, against a backdrop of a legal environment that ranges from gaping holes to regulatory vacuum, research organizations and early-adopting industry players push ahead with the new technology. Not being able to create any breathing room for lengthy political and legal considerations, the last 15-20 years have seen several governments adopting voluntary environmental programs (VEPs), arguing that this is the only viable proportional option for the time being. It is estimated that there are some 300 VEPs in the European Union and over 200 in the United States, dealing with matters such as climate change, energy, waste, water, toxic materials, agriculture, manufacturing, mining, forestry, hotels, hospitals, and financial institutions. If these voluntary programs work is subject to debate - some apparently do, some less so. In the case of manufactured nanomaterials, the risk properties remain largely unknown and it is unclear what exactly should be regulated. For the VEPs that are in place for nanomaterials, governments are urging companies to submit health and safety information on the nanomaterials they produce or commercialize. In order to investigate whether voluntary government programs will be sufficient to ensure the safety of manufactured nanomaterials, researchers have analyzed a sampling of voluntary programs in the fields of environmental health and safety in the United States over the past 20 years, with a view towards their applicability in the case of manufactured nanomaterials

Posted: Nov 29th, 2007

Some nanotechnology risks worry scientists more than the public

The benefits of new technologies, whether they are new medical treatments, an innovative approach to farming or new ways of generating energy, almost always come with some new risks as well. In the emerging stages of a new technology, experts and the public generally differ in their perceptions of risk. While this might be due to social and demographic factors, it is generally assumed by scientists who conduct risk research that experts' risk assessments are based more strongly on actual or perceived knowledge about a technology than lay people's risk assessments. Nevertheless, whether the risks are real or not, the public perception of an emerging technology will have a major influence on the acceptance of this technology and its commercial success. If the public perception turns negative, potentially beneficial technologies will be severely constrained as is the case for instance with gene technology. It is not surprising that a new study found that, in general, nanoscientists are more optimistic than the public about the potential benefits of nanotechnology. What is surprising though, is that, for some issues related to the environmental and long-term health impacts of nanotechnology, nanoscientists seem to be significantly more concerned than the public.

Posted: Nov 26th, 2007

On beating cancer (with nanotechnology)

Cancer is an enormous socio-economic problem. According to the National Cancer Institute (NCI), it is estimated that in 2007 there will be over 1.4 million new cases of cancer (of any type) and over 550,000 deaths from cancer in the United States (you can download a detailed Cancer Statistics 2007 Presentation; ppt download, 808 KB) from the American Cancer Society. This makes cancer the second deadliest disease category, after heart diseases. But while the mortality rates for heart diseases have dropped by more than half from 1950 to 2004, and other major disease categories show similar trends, cancer death rates have stayed pretty much the same. Shocking but true, if you are a male living in the U.S., your lifetime probability of developing some type of cancer is 1 in 2. If you are female, your probability is 1 in 3. Equally dismal are the economic cost associated with this disease: The amount of direct cancer-related costs (treatment, care and rehabilitation) have reached $74 billion in the U.S. in 2005, and growing fast, while the overall economic costs (including loss of economic output due to days off and premature death) are estimated to be over $200 billion per year (2005 data). This Spotlight will discuss existing and new approaches to fight cancer and their limitations. The goal is to stimulate readers to support and participate in interdisciplinary research and teaching efforts toward relieving suffering and death due to cancer. Fighting cancer involves three phases: (i) detection, (ii) treatment, and (iii) monitoring. Success depends on matching science to the actual practical needs. We'll take a look at - in particular nanotechnology - efforts underway in the direction of these three phases and comment on some of the practical problems encountered fighting cancer. We also speculate about some unconventional research that might be successful fighting cancer in the future.

Posted: Oct 31st, 2007

Old world masterpieces may benefit from a nanotechnology cleaning

In the art world, the topic of conservancy is a heated one. Some believe that the world's most precious works of art should be allowed to age and die gracefully, while others believe they should be protected and restored at all costs. Art conservation and restoration is not a modern phenomenon. Within 20 years of its 1497 completion, one of the world's most well-known and admired works of art, The Last Supper, was already beginning to show signs of wear and exposure. In 1726, the first of many restorations (or attempted restorations) occurred, followed by additional restorations in 1901, 1908, 1924, and 1951. The deterioration proved unstoppable, while the effects of pollution added to the masterpiece's worsening condition. Between 1978 and 1999, another major restoration effort was undertaken. In 1981, the decision by the Vatican to restore the Sistine Chapel's ceiling sparked a tremendous debate. Today, the Mona Lisa stirs similar debate. Although the world's most famous painting has severe yellowing and shows other signs of aging (it is 500 years old after all), the Louvre has adamantly refused to even consider restoration or cleaning. You can't really blame them. While the cleaning and restoration of the Sistine Chapel and the Last Supper has certainly improved their visibility, restoration is not an exact science and the process could save or destroy the famous work. In fact, much of the yellowing we see today on masterpieces such as the Mona Lisa and the Last Supper are the result of varnishes originally applied to protect the paintings. The process of cleaning and removing old varnish is a tedious and painstaking process, but Italian chemists may have found a much better, and safer, process with the help of nanoparticles.

Posted: Oct 22nd, 2007

Nanotechnology patents and the future of the pharma industry

Medicine is big business. The big pharma companies have traditionally enjoyed enormous profits that would make the eyes of other companies' CEOs water (apart from big oil companies, of course). The combined annual net income for the top 10 pharma companies (ranked by market capitalization) currently is about $73 billion. Pfizer alone has a net income of approximately $19 billion. The recipe for success? Patent protection and intellectual property rights (IPRs). The core of Big Pharma's business model relies on patent protection for their blockbuster drugs, which allows them to sell these drugs at extraordinarily high profit margins that they wouldn't be able to generate in a competitive market. Point in case: Lipitor, the cholesterol-lowering drug that accounts for nearly $13 billion of Pfizer's revenues and over 40% of its profits. Another key part of the pharma business model is heavy spending on sales and marketing. Novartis, for instance, is spending around 33% of sales on promotion, compared with about 19% on R&D, although the cost of bringing a new drug to market could well exceed $1 billion (and that is also the argument pharma companies use to justify their profits). However, pharmaceutical companies are faced with the expiration of the patent protection on their main profit generators, they have relatively few new products in the pipeline, and they need to come to terms with the emerging nanomedicine landscape. While nanomedicine potentially offers promising new value propositions and revenue streams, for instance in diagnostics, it also could completely displace certain classes of drugs such as current chemotherapy agents with novel nanoparticle reformulations. In what looks like more of the same though, it seems that the future of nanomedicine business will also depend on patents and IPRs, potentially even more so than today.

Posted: Oct 12th, 2007

Collaboration is key to protecting nanotechnology workers

In an earlier Spotlight we reported on NIOSH's Nanotechnology Research Center (NTRC) and its efforts concerning the occupational safety and health perspectives of engineered nanomaterials (Nanotechnology in the workplace). Today, we are looking at the specific steps undertaken by companies active in the field. "We were receiving a steady stream of questions from industry and academia regarding what we knew about the hazards of nanomaterials," Charles L. Geraci, Branch Chief at the National Institute of Occupational Safety and Health (NIOSH) and Co-Coordinator of the NIOSH Nanotechnology Field Team, tells Nanowerk. "People were coming to NIOSH for recommendations; we knew we needed to have a better understanding of the nature of workplace exposure during research, production and use." But, in a new and relatively little studied area of industry, where does one find these answers? NIOSH already had a strong research program to address questions in the lab, says Geraci, but field data was needed to have a complete picture. "In our minds, the best way to achieve this was to do what NIOSH does best: get in the field and gather data through observation and measurement." In 2006, the concept of a field team dedicated to this effort was developed.

Posted: Oct 9th, 2007